Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1162-1167

  Ramachandran, Geetha ^a   Kumar, A K Hemanth ^a   Bhavani, P K ^a   Kannan, T ^a   Kumar, S Ramesh ^a   Gangadevi, N Poorana ^a   Banurekha, V V ^a   Sekar, L ^a   Ravichandran, N ^b   Mathevan, G ^c   Sanjeeva, G N ^d   Dayal, Rajeshwar ^e   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b Government Hospital of Thoracic Medicine   (India)

^c Government Rajaji Hospital   (India)

^d INDIRA GANDHI INSTITUTE OF CHILD HEALTH   (India)

^e S N MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CHILD; DIRECTLY OBSERVED THERAPY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TUBERCULOSIS; CLINICAL TRIAL; HIV INFECTIONS; INFANT; PRESCHOOL CHILD; REGRESSION ANALYSIS;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INDIA; INFANT; ISONIAZID; MALE; PYRAZINAMIDE; REGRESSION ANALYSIS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84921906043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04338-14     Document Type: Article

References (31)

1. Dye C, Scheele S, Dolin P, Pathana V, Raviglione MC. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677-686.
2. Braun MM, Badi N, Ryder RW, Baende E, Mukadi Y, Nsuami M, Matela B, Williame JC, Kaboto M, Heyward W. 1991. A retrospective cohort study of the risk of tuberculosis among women of child bearing age with HIV infection in Zaire. Am Rev Respir Dis 143:501-504. http://dx .doi.org/10.1164/ajrccm/143.3.501.
3. Harries AD. 1990. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet 335:387-390. http://dx.doi.org/10 .1016/0140-6736(90)90216-R.
4. Jones D, Malecki J, Bigler W, Witte JJ, Oxtoby MJ. 1999. Pediatric tuberculosis and human immunodeficiency virus infection in Palm Beach County, Florida. Am J Dis Child 146:1166-1170.
5. Swaminathan S. 2004. Tuberculosis in HIV-infected children. Paediatr Respir Rev 5:225-230. http://dx.doi.org/10.1016/j.prrv.2004.04.006.
6. Jeena PM, Pillay P, Pillay T, Coovadia HM. 2002. Impact of HIV-1 coinfection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 6:672-678.
7. Rekha B, Swaminathan S. 2007. Childhood tuberculosis: global epidemiology and the impact of HIV. Paediatr Respir Rev 8:99-106. http://dx.doi .org/10.1016/j.prrv.2007.04.010.
8. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Soumya Swaminathan Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P. 2004. Decreased bioavailability of rifampin and other anti-TB drugs in patients with advanced HIV disease. Antimicrob Agents Chemother 48:4473-4475. http://dx.doi.org/10.1128/AAC.48.11.4473-4475.2004.
9. Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Sequin I, Oliveras L, Walker S, Rachlis A, Cameron DW. 1997. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection. Ann Intern Med 127: 289 -293. http://dx.doi.org/10.7326/0003-4819 -127-4-199708150-00006.
10. Peloquin CA, MacPhee AA, Berning SE. 1993. Malabsorption of antimycobacterial medications. N Engl J Med 329:1122-1123. http://dx.doi .org/10.1056/NEJM199310073291513.
11. Berning SE, Huitt GA, Iseman MD, Peloquin CA. 1992. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 327:1817-1818. http://dx.doi.org/10.1056/NEJM199212173272514.
12. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. 2006. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 50:407-413. http://dx.doi.org/10.1128/AAC.50.2.407-413.2006.
13. Schaaf HS, Willemse M, Cilliers K, Labadarios D, Maritz JS, Hussey GD, Mcllleron H, Smith PJ, Donald PR. 2009. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med 7:19-29. http://dx.doi.org/10.1186/1741-7015-7-19.
14. Thee S, Seddon JA, Donald PR, Seifart SI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS. 2011. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 55:5560-5567. http://dx.doi.org/10.1128/AAC.05429-11.
15. Revised National Tuberculosis Control Programme. Technical and operational guidelines for tuberculosis control, October 2005. Ministry of Health and Family Welfare, New Delhi, India. http://tbcindia.nic.in/pdfs /Technical%20&%20Operational%20guidelines%20for%20TB %20Control.pdf.
16. Sarma GR, Kailasam S, Datta M, Loganathan GK, Rahman F, Narayana ASL. 1990. Classification of children as slow or rapid acetylators based on concentrations of isoniazid in saliva following oral administration of body weight and surface area: related dosages of the drug. Indian Pediatr 27: 134-142.
17. Kumar AKH, Sudha V, Ramachandran G. 2012. Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in plasma. SAARC J TB Lung Dis HIV/AIDS 9:13-18. http://dx.doi.org/10.3126/saarctb.v9i1.6960.
18. Kumar AKH, Chandra I, Geetha R, Chelvi KS, Lalitha V, Prema G. 2004. A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine. Indian J Pharmacol 36:231-233.
19. World Health Organization.2011. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. Technical report series no. 854. World Health Organization, Geneva, Switzerland. http://www.who.int/childgrowth/publications/physical-status/en/index .html.
20. Palme IB, Gudetta B, Bruchfeld J, Muhe L, Giesecke J. 2002. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J 21:1053-1061. http://dx.doi.org/10.1097 /00006454-200211000-00016.
21. Alsultan A, Peloquin CA. 2014. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74:839-854. http://dx.doi .org/10.1007/s40265-014-0222-8.
22. McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR. 2009. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis 48:1547-1553. http://dx.doi.org/10 .1086/598192.
23. Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, Soumya Swaminathan. 2013. Age, nutritional status and isoniazid acetylator status influence pharmacokinetics of anti-TB drugs in children. Int J Tuberc Lung Dis 17:800-806. http://dx .doi.org/10.5588/ijtld.12.0628.
24. Schaaf HS, Parkin DP, Seifart HI, Werely J, Hesseling PB, van Helden PD, Maritz JS, Donald PR. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 90:614-618. http://dx .doi.org/10.1136/adc.2004.052175.
25. Seifart HI, Donald PR, de Villiers JN, Parkin DP, Jaarsveld PP. 1995. Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen. Ann Trop Paediatr 15:249-254.
26. Seth V, Beotra A, Bagga A, Seth SD. 1992. Drug therapy in malnutrition. Indian Pediatr 29:1341-1346.
27. Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S. 1993. Serum concentrations of rifampicin and isoniazid in tuberculosis. Indian Pediatr 30:1091-1098.
28. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. 2013. Isoniazid, rifampin and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 57: 3614-3619. http://dx.doi.org/10.1128 /AAC.02468-12.
29. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 48:1685-1694. http://dx.doi.org/10.1086/599040.
30. Heysell SK, Moore JL, Keller SJ, Houpt ER. 2010. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16:1546-1553. http://dx.doi .org/10.3201/eid1610.100374.
31. Pasipanodya JG, Mcllleron H, Burger A, Wash PA, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis /jit352.